Orphazyme announces confidential submission of a draft registration statement for a potential registered public offering in the United States

by | Jul 2, 2020

Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company harnessing the amplification of the Heat-Shock Proteins in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (“SEC”) relating to a potential registered public offering of the Company’s ordinary shares, in the form of American Depositary Shares (“ADSs”), in the United States.  


Press inquiries should be adressed to:

Sten Verland, PhD MSc

General Partner